FibroBiologics, Inc. Common Stock
- FBLG
- NASDAQ
- Biotechnology
- Clinical-Stage Biotech
- Fibroblast Therapies
$0.95
Today −2.15%Quote Oct 19, 2026, 05:35 PM UTC
−34.61%over the last month
Max drawdown −36.0%From 1-month high −34.6%3 months +24.3%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About FibroBiologics, Inc. Common Stock
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
15
Founded
2021
Market value
$6.3M
Quote Oct 19
Analyst target
$180.00
+18845.4% from here
Floor
$0.95
0.0% below price
Resistance
$1.04
9.5% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about FBLGPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free